Skip to content

Meloxicam

    Brands

    DEA Class; Rx

    Common Brand Names; Mobic, Vivlodex, Anjeso, Qmiiz

    NSAIDs

    Oral and parenteral nonsteroidal anti-inflammatory drug (NSAID)
    Used for osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis and moderate or severe pain alone or in combination with other non-NSAID analgesics
    Associated with increased risk of serious cardiovascular or gastrointestinal (GI) tract adverse effects

    For the relief of the signs and symptoms of osteoarthritis.
    For the relief of the signs and symptoms of rheumatoid arthritis.
    For the relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).
     

    Known hypersensitivity (eg, anaphylactic or serious skin reactions)

    History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs

    Perioperative pain management in the setting of coronary artery bypass graft (CABG) surgery

    Anjeso: Moderate-to-severe renal insufficiency in patients at risk for renal failure owing to volume depletion

    Qmiiz: Phenylketonuria

    >10%

    Borderline elevations of one or more LFTs (<15%)

    1-10%

    Abdominal pain

    Anorexia

    Diarrhea

    Nausea

    Pyrosis

    Gastritis

    Flatulence

    Constipation

    Steatorrhea

    Upper GI ulcers, gross bleeding/perforation (1% of patients treated for 3-6 mth and 2-4% of those treated for 1 yo)

    Increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal

    Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs

    The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease; however, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events

    Increased CV thrombotic risk has been observed most consistently at higher doses

    Minimize potential risk by using lowest effective dose for the shortest duration possibleCABG

    Pregnancy; Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive

    Lactation: Human data are not available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production

    Adults

    15 mg/day PO for tablets, including oral disintegrating tablets, and suspension; 10 mg/day PO for capsules; 30 mg/day IV.

    Geriatric

    15 mg/day PO for tablets, including oral disintegrating tablets, and suspension; 10 mg/day PO for capsules; 30 mg/day IV.

    Adolescents

    0.125 mg/kg/day (Max: 7.5 mg/day) PO for tablets, including oral disintegrating tablets, and suspension; safety and efficacy have not been established for capsules or IV injection.

    Children

    2 to 12 years: 0.125 mg/kg/day (Max: 7.5 mg/day) PO for tablets, including oral disintegrating tablets, and suspension; safety and efficacy have not been established for capsules or IV injection.
    1 year: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    tablet (Mobic)

    • 7.5mg

    • 15mg

    tablet, oral distintegrating (Qmiiz)

    • 7.5mg

    • 15mg

    capsule (Vivlodex)

    • 5mg

    • 10mg

    injection, IV aqueous dispersion (Anjeso)

    • 30mg/mL single-dose vial